Home>Topics>Stocks>Lexicon Pharmaceuticals

Lexicon Pharmaceuticals LXRX

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. More Positive News For Lexicon, But Not The Big Announcement


      Tue, 15 Apr 2014

      By Stephen Simpson, CFA : Lexicon Pharmaceuticals ( LXRX ) continues to generate data on its SGLT-1/2 inhibitor LX4211 that suggest this is an effective and promising medication for

    2. Lexicon Pharmaceuticals' CEO Discusses LX4211 Positive Results in Type 1 Diabetes Clinical Trial (Transcript)


      Mon, 14 Apr 2014

      Lexicon Pharmaceuticals , Inc. ( LXRX ) LX4211 Positive Results in Type 1 Diabetes Clinical Trial Special Call April 14, 2013 08:30 AM ET Executives Arthur Sands

    3. Lexicon diabetes drug performs well in Phase II trial


      Mon, 14 Apr 2014

      Lexicon Pharmaceuticals ( LXRX ) LX4211 oral treatment for Type 1 diabetes has reached the primary endpoint of a Phase II trial of 33 patients by reducing the

    4. lxrx not for now.


      Fri, 4 Apr 2014

      Despite a pipeline, lexicon pharma does not look cheap. At a valuation today of nearly 900 million, and an expensive road to drug approval, we should all expect continuing dilution of this equity. To my mind, the only reason to invest is for a catalyst gap up. Their diabetes drug looks intriguing,

    5. M* 5 Star Stocks


      Sat, 22 Mar 2014

      the criterion of "5 stars." I only got 6 stocks, none of them were familiar to me. Can this be right? Alumina AWCMY Buenaventure Mining BVN Fiat Group FIATY Lexicon Pharmaceuticals LXRX Petroleo Brasileiro SA Petrobras ADR BPR Posco PKX

    6. LXRX . Morningstar rating change


      Fri, 7 Feb 2014

      Morningstar rating change from 4-5 Stars. Does anyone buy or sell, based on M rating changes?

    7. Lexicon's Staff Cut and CEO Exit Reflect High Costs of Diabetes Drug Development


      Mon, 13 Jan 2014

      Lexicon Pharmaceuticals announced that longtime CEO and cofounder Arthur Sands plans to depart the firm, and that it will cut 45% of its workforce

    8. New Morningstar Analyst Report for Lexicon Pharmaceuticals , Inc.

      Stock Reports

      Thu, 19 Dec 2013

      background in cardiovascular disease and endocrinology, which is critical for the firm's LX4211 program. Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising

    9. Lexicon's 2Q Results In Line With Our Expectations; Key Catalysts Remain in 2013


      Tue, 30 Jul 2013

      Lexicon Pharmaceuticals LXRX reported second-quarter results that put it on track to meet our forecast for the year, and we're maintaining our $3.50

    10. Lexicon's 4211 Looks Strong in Midstage Trial, We Expect Partner and Late-Stage Trials in 2013


      Mon, 25 Jun 2012

      Lexicon LXRX has released data from a Phase 2b study of LX4211, and we're maintaining our fair value estimate as we expect the firm to move

    « Prev1234Next »
    Content Partners